SOURCE: Ventana Medical Systems, Inc.

May 10, 2006 08:00 ET

Ventana Announces Symphony Commercial Launch

TUCSON, AZ -- (MARKET WIRE) -- May 10, 2006 -- Ventana Medical Systems, Inc. (NASDAQ: VMSI) today announced the commercial launch of its fully automated Symphony H&E, or primary staining system for use in clinical histology and drug discovery laboratories.

Commenting on the launch, Christopher Gleeson, President and CEO, said, "We are pleased to have reached this important milestone for our Company and look forward to the remainder of 2006 as we introduce the Symphony system to clinical and pharmaceutical drug discovery laboratories in North America and Europe. There is every indication that the Symphony will combine substantially improved productivity with exceptional staining quality which will benefit both our customers and the patients they serve."

Ventana develops, manufactures, and markets instrument/reagent systems that automate slide preparation and staining in clinical histology and drug discovery laboratories worldwide. Ventana's clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. Ventana's drug discovery systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug compounds.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Federal Securities laws. These forward-looking statements include our expectations for the performance of new products and benefits to customers and patients. These forward-looking statements are subject to numerous risks and uncertainties, and actual results may vary materially. We may not realize anticipated future results, and new products may not be as successful as we expect in terms of customer rates of adoption. Other risks and uncertainties include risks associated with the development, manufacturing, marketing, and sale of medical products, competitive factors, general economic conditions, legal disputes, and government actions, and those other risks and uncertainties contained in our most recent Annual Report filed with the Securities and Exchange Commission (SEC) on Form 10-K, and all subsequent SEC filings. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis retrieval system (EDGAR) at www.sec.gov. We undertake no obligation following the date of this release to update or revise our forward-looking statements or to update the reasons actual results could differ materially from those anticipated in forward-looking statements. We caution you not to place undue reliance upon any such forward-looking statements, which speak only as of the date such statements are made. Past performance is not indicative of future results. We cannot guarantee any future operating results, activity, performance, or achievement.

Visit the Ventana Medical Systems, Inc., website at www.ventanamed.com.

Contact Information

  • Contact:
    Christopher M. Gleeson
    President and CEO
    (520) 229-3787

    Nick Malden
    Chief Financial Officer
    (520) 229-3857

    Ventana Medical Systems, Inc.
    1910 E. Innovation Park Drive
    Tucson, Arizona 85755
    (520) 887-2155